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Abstract
The pathology of Alzheimer’s disease (AD) features amyloid β
peptide deposition, intracellular neurofibrillary tangles and deficits
in the cholinergic pathway. Abnormal blood pressure is recognised
as a risk factor for the development of AD, although the underlying
mechanisms remain unproven. This review proposes angiotensins
and associated enzymatic pathways as important mediators of
recognised but undefined links between blood pressure and AD.
Evidence in support of this involvement translates consistently from
the most basic in vitro, in vivo and ex vivo experimental paradigms
to more complex human-based observational and experimental
studies, which also fortunately offer potential for therapeutic
interventions against AD.
Prevailing hypotheses of Alzheimer’s disease
pathogenesis
Alzheimer’s disease (AD) [MIM 104300], as the most
common form of progressive dementia, is characterised
neuropathologically by the presence of intracellular
neurofibrillary tangles and features resulting from the
deposition of amyloid β-peptide (Aβ) extracellularly in the
form of senile plaques and within blood vessels in the brain in
the form of cerebral amyloid angiopathy. The pathogenesis of
AD is understood to be partly explained by mechanisms
involved with (but not restricted to) two of the most prevailing
hypotheses: the Aβ cascade hypothesis and the cholinergic
hypothesis. The Aβ cascade hypothesis, which developed in
the early 1980s, suggests that the commonly observed
neurodegenerative abnormalities of AD, particularly senile
plaques, develop following the accumulation of the 39 to 42
amino acid peptide Aβ in the brain [1]. This accumulation of
Aβ is likely a consequence of imbalance between production
of Aβ from amyloid precursor protein (APP; Figure 1) and its
removal. Aβ removal can be mediated via drainage through
interstitial fluid in the space surrounding blood vessels in the
brain, by receptor-mediated transport of Aβ from the brain to
the peripheral circulation, by enzymatic degradation or
various combinations of all the these [1]. Over the years the
Aβ hypothesis has not been universally accepted due to its
perceived failing that brain Aβ deposition correlated poorly
with cell death or disease severity in AD whereas
neurofibrillary tangle pathology, another established
neuropathological hallmark for AD, correlated better and, as
such, was suggested to be more relevant, with Aβ repre-
sentative of a secondary phenomenon [2]. Yet this failing was
arguably addressed in the past decade with the identification
of soluble and diffusible oligomeric forms of Aβ that are now
thought to be the more harmful forms and which have been
correlated with AD pathogenesis [3]. Furthermore, questions
have now arisen as to whether neurofibrillary tangles are
merely a marker of disease progression and not, in fact, a
mediator of cell death as has been proposed (see [3,4] for
reviews).
The cholinergic hypothesis posits that loss of cholinergic
function (derived from the action of the neurotransmitter
acetylcholine (ACh)) in the central nervous system is a
significant part of the cognitive decline associated with AD
(see [5] for a review; Figure 1). This hypothesis pre-dates the
seeds of the Aβ cascade hypothesis but is supported by
considerable evidence that there is reduced synthesis and
altered transport of ACh, selective loss of cholinergic neurons,
disruption of ACh receptor signalling, as well as reductions in
the levels of these receptors in AD brains (see [5] for a
review). Indeed, the majority of licensed ‘cholinesterase’
therapeutics currently used to treat and partially delay some of
the progressive symptoms of AD are drugs that target
acetylcholinesterase-mediated breakdown of ACh, thereby
increasing the amount and prolonging the life of ACh in the
brain [5]. Importantly, neither of the properties of these
hypotheses exist in isolation and there is now a body of
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evidence supporting complex levels of interaction between the
two and, more than likely, with other systems that fall beyond
the scope of this review (see [5] for a review; Figure 1).
The renin angiotensin system
The renin angiotensin system (RAS) is best known for its role in
the kidney in controlling blood pressure and bodily fluid
homeostasis. The ‘classical’ RAS is known by the role of renin
in cleaving inactive angiotensinogen to produce angiotensin
(Ang)I, which is, in turn, converted by angiotensin-1 converting
enzyme (ACE) to the (vaso-)active AngII [6]. AngII exerts its
well known hypertensive effects following binding to its two
receptors (AT1R and AT2R) [7]. However, the past two
decades have revealed that the classical RAS was only the tip
of the iceberg of what is now known to be a very complex
system involving new AngI and AngII metabolites, additional
receptors and regulating mechanisms (see [7] for a review;
Figure 2). This added complexity has also offered new potential
therapeutic targets for hypertension in addition to those already
targeting the RAS through inhibition of ACE (ACE inhibitors
Figure 1
Schematic of amyloid precurser protein metabolism, from which amyloid β peptide can be produced. The amyloid precurser protein (APP) amino
acid sequence is given in the single letter code with the boxed sequence representing the amyloid β peptide (Aβ). The red arrows denoted by β
and γ represent the major β- and γ-secretase cleavage sites on APP from which Aβ is produced in the amyloidogenic pathway. The green arrow
denoted by α pointing to the highlighted lettering shows the vicinity of the major α-secretase site on APP, which precludes the formation of APP in
the anti-amyloidogenic pathway. The blue arrows labelled ACE show the proposed amino acids that are involved in (anti-amyloidogenic denoted by
a question mark) ACE-mediated cleavage of Aβ, which were suggested to be either Asp7-Ser8 based on the detection of Aβ8-40 fragments or
Arg5-His6 [8,32]. Interestingly, isomerisation (that is, having the same molecular formula but having a different structure and sometimes different
properties) of the Asp7 (isoAsp7) residue of Aβ, a common age-related and possible conformational modification that is more prevalent in
Alzheimer’s disease (AD), resulted in more efficient cleavage than the non-modified Asp7 in vitro. It has thus been suggested that the main
cleavage site of angiotensin-1 converting enzyme could be Arg5-His6 and the identification of Aβ8-40 cleavage products detected previously might
be the result of subsequent hydrolysis of Aβ6-40 fragments. The blue horizontal arrows of different sizes and pointing in opposite directions
indicate that the majority of APP processing throughout a lifetime is anti-amyloidogenic but that in AD there is evidence of some increased
amyloidogenic processing (denoted by the dashed arrow). Negative effects on the cholinergic pathway resulting from Aβ activity are shown, as are
reported complex feedbacks between cholinergic receptors and APP processing (see [5] for a review). ChAT, choline acetyltransferase.(ACE-Is)) or by preventing AngII from binding its receptors
(angiotensin receptor blockers (ARBs)) [8] (Figure 2).
The relevance of the renin angiotensin
system to Alzheimer’s disease
Epidemiological clues?
Hypertension is a recognised risk factor for cerebrovascular
disease, coronary heart disease and increased cardiovascular
morbidity and mortality [9] and its treatment with drugs such
as RAS-acting ACE-Is and ARBs lessens morbidity and
mortality and improves quality of life and preserves cognitive
function [10]. Like dementia, hypertension incidence increases
with age and is thought to affect almost half of people aged
over 70 years [9]. The association between hypertension and
dementia appears to be more than coincidental and the
balance of findings from longitudinal and cross-sectional
studies suggest that elevated mid-life blood pressure
precedes the development of AD, although in the years
preceding dementia onset the hypertension appears to
lessen [9]. This observation has been suggested to be a
secondary phenomenon [9], possibly due to hypertension
related pathologies that interestingly are also relevant in AD
[11]. Indeed, some studies have reported hypertension
related elevations in neurofibrillary tangle numbers and
atrophy in the regions of the brain relevant to AD (reviewed
by Papademetriou [10]); however, apart from these findings
any other mechanistic links between hypertension and AD
have been lacking.
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Figure 2
Schematic representation of the renin angiotensin system. Additional components of the renin angiotensin system (RAS) pathway have been
identified in recent years, increasing its complexity. The ‘classical’ components of the system are highlighted in bold and by underlined text
(modified from [8] and incorporating parts of the discussion from [50]). Angiotensin metabolites are prefixed by Ang, with the number of amino
acids present relative to the 14 amino acid angiotensinogen sequence order. Black arrows between peptide fragments denote enzymatic
conversion steps catalyzed by a host of enzymes denoted in coloured circles or boxes according to the abbreviations listed below. Blue arrows
from peptides to blue boxes denote receptor binding routes according to the main text. Note that the AngII metabolite AngIII is currently considered
to be the main and a more potent mediator of many recognised AngII functions [50], and the binding of AngIV to its receptor is believed to affect
cognitive function [40]. Also note the ACE2-Ang(1-7)-Mas (receptor) axis, which is now currently believed to be a RAS internal regulatory
mechanism to attenuate AngII-mediated functions (large red arrow centrally located in pathway; ACE2 is a recently discovered ACE homologue)
[50]. Abbreviations: ACE, angiotensin-1 converting enzyme; AP, aminopeptidase; DAP, dipeptidyl aminopeptidase; PCP, carboxypeptidase; PO,
propyl oligopeptidase; REN, renin.The involvement of renin angiotensin system genes in
Alzheimer’s disease
With the exception of a single study of hypertension-
associated genetic variants in the renin and angiotensinogen
genes that found no association with AD, the bulk of
investigations of RAS genes for AD susceptibility have
focussed on ACE1, which encodes the RAS rate-limiting
enzyme ACE [12]. ACE1 is interesting because of the role of
ACE in hypertension and vascular disease but also because
previous studies on familial hypertension on a common Alu
insertion/deletion (I/D; indel) polymorphism (rs1799752)
within intron 16 of ACE1 found this locus to be ‘functionally
associated’ with plasma levels of ACE. The reputed functional
association was such that homozygosity for the D and I alleles
correlated with the highest and lowest levels of ACE,
respectively, while heterozygotes had intermediate levels [13].
Current estimates are that ACE1 contributes to 20% of the
total variation in serum ACE concentration and 16 to 24% of
the variation in ACE activity, although the underlying
mechanism for this association remains unclear since two
functional sites within ACE1 might be involved [14].
The first positive association between the ACE1 indel and AD
was published in 1999, where ACE1 variants were associated
with AD independent of the already well recognised risks
associated with variants in APOE (the gene encoding
apolipoprotein E) [15]. Since then the balance of evidence
from over 30 replication case-control studies and a number of
meta-analyses, including that of the continually updated online
meta-analyses ‘AlzGene’ database (gene ID 125) [12],
continues to support a possible (albeit modest) correlation
between ACE1 variation and risk of AD [12]. Studies of other
ACE1 variants that also ‘tag’ the previously reported AD risk
alleles have also supported ACE1  involvement in AD, with
reported association between extended ACE1 variants (that is,
haplotypes) and AD risk, smaller brain hippocampal and
amygdalar volumes, lower (less beneficial) levels of cerebro-
spinal fluid (CSF) Aβ and age of AD onset [15-18]. Further
evidence supporting ACE1 and AD risk has come from a new
generation of genome-wide association studies and from
genes deemed to have the strongest ‘signals’ in the AlzGene
database in large family-based and case-control studies.
Generally, ACE1 consistently appeared to have some level of
association that, in most cases, disappeared after various
corrections for statistical analyses were made or only remained
significant when secondary (for example, gene-gene inter-
action) analyses were conducted [16,18-20]. Although not all
studies agree with the involvement of ACE1 in AD risk on the
balance of current evidence, any genetic involvement of ACE1
in AD is likely modest, complex and requires interaction with
other genes or factors [15,19].
Alzheimer’s disease-related alterations to the renin
angiotensin system
Prior to any evidence of genetic association between ACE1
and AD, a limited number of small and methodologically
diverse studies examined the vascular role of ACE and other
RAS components in the central nervous system of AD
patients and controls. There have been various reports of
increased ACE activity that correlated with mean Aβ senile
plaque load and Braak stages, increased ACE binding
density, increased neuronal and perivascular ACE immuno-
reactivity - which was also found to correlate with levels of
parenchymal Aβ load and increased Aβ deposition in blood
vessels (that is, cerebral amyloid angiopathy) [21-23] (see
[23,24] for reviews) - as well as increased AngII and AngII
receptor (AT1R, AT2R) binding or immunoreactivity in AD
brain [21,25]. Other studies have reported reduced ACE
levels in CSF of AD patients [25,26], no differences in ACE
activity or levels [27,28] or elevated ACE activity [21]. Two
studies reported no statistically significant associations but
there were data trends between the presence ACE1 indel
risk genotypes and the 42 amino acid variant of Aβ (Aβ42)
load in AD [29] and ACE protein level (but not ACE activity)
in post mortem CSF from AD patients [21]; the latter
observation is consistent with the association between ACE1
indel variation and plasma ACE [13,30], where ACE was also
found to be reduced in AD patients [31]. There are some
obvious disparities across the various studies, but these are
likely explained by the variety of methodologies used over the
years and, in some cases, relatively small sample numbers.
On balance, in AD there does appear to be either a primary
(that is, potentially causative effect leading to AD) or
secondary (that is, a manifestation arising from AD
pathogenesis) disturbance to components of the RAS.
Renin angiotensin system function in cell-based and
animal models of Alzheimer’s disease
The in vitro findings that the ACE-I lisinopril could interfere
with ACE’s ability to inhibit the aggregation, deposition and
fibril formation of the 40 amino acid variant of Aβ (Aβ40), as
well as to reduce Aβ-mediated toxic effects on rat cells,
provided a possible model (that is, ACE can degrade Aβ) for
ACE involvement in AD. When the Aβ degrading properties
are viewed alongside the influence of ACE1 variants on ACE
levels, it is possible to envisage a model whereby AD-
associated ACE1 risk variants that reduce plasma levels of
ACE [13] - and possibly levels in the CSF [21] - could impact
on a person’s ability to degrade Aβ. Further cell-based and in
vitro studies supported these findings (see [8] for further
discussion), although there remains uncertainty as to the
amino acids of Aβ where ACE cleavage takes place and
whether these sites are the same in vivo for full length Aβ
compared to some shorter Aβ fragments on which
experiments to identify the site of cleavage were conducted
(Figure 1) [8,32].
Initial animal studies to test whether ACE-mediated Aβ
cleavage is evident in vivo and whether ACE-Is might
interfere with Aβ pathology found no supportive evidence [8].
However, subsequent studies found ACE-mediated enzy-
matic conversion of Aβ42 to Aβ40 and their subsequent
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as increased Aβ deposition in mice chronically administered
the ACE-I captopril [33]. Transgenic mouse models of AD
given the ARB valsartan also demonstrated improved spatial
learning and attenuated oligomerisation of Aβ [34], while low
doses of the ARB olmesartan improved hippocampal
synaptic plasticity and Aβ-mediated cerebrovascular
dysfunction, which included impairment of the autoregulatory
mechanisms involved with cerebral blood flow [35]. It has
been suggested that the differences between these studies
are not related to species-influenced differences in the
degradation of human Aβ (that is, from human transgenes in
animal models) by mouse ACE [36]. A more likely explanation
lies with differences in the experimental designs between the
studies. Animals that commenced longer periods of treatment
at a more mature age but prior to the development of Aβ-
related pathology (possibly resembling middle age treatment
for hypertension) tended to demonstrate evidence of ACE-
mediated Aβ degradation and how ACE-Is might have
adverse effects. Clearly, further studies are now needed
given the potential significance of these findings.
Effects of angiotensins and anti-angiotensin treatments
on cognition
Apart from the role of AngII in the development of essential
hypertension, the angiotensins (AngII, AngIII and AngIV;
Figure 2) acting on the angiotensin receptors AT1R and AT2R
and the putative angiotensin receptor AT4R play a significant
role in cognition and anxiety, detailed discussion of which is
not possible in this article (see [37] for an overview). In
addition to the potential of ACE in mediating Aβ degradation
as a mechanism in AD, there are also data strongly suggest-
ing that AngII inhibits potassium-mediated release of ACh
from slices of rat entorhinal and human temporal cortex,
demonstrating a specific interaction between angiotensin
signalling and the cholinergic system [38]. AngII has also
been shown to influence tumour necrosis factor α and
transforming growth factor β signalling, blood brain barrier
(BBB) maintenance and cell survival (via AT1R and AT2R
receptors and a positive effect on the activity of plasmin,
another Aβ degrading enzyme), all of which contribute to and
are familiar aspects of AD pathogenesis [39]. In addition to
AD-associated alterations in AngII receptor immunoreactivity
[21,25], distorted neuronal processes in hippocampal AngII-
immunopositive cells in senile plaques [23], and the growing
literature that the AngII metabolite AngIV may offer additional
glucose transport linked therapeutic routes to improve
cognition (see [40] for discussion), it is clear that AngII and
its signalling pathway through its receptors are implicated in a
number of facets of AD pathogenesis.
The significance of these properties is further emphasised by
the likely links between hypertension and dementia and,
unsurprisingly, has led over the years to the consideration of
how anti-hypertensive treatments (ACE-Is and ARBs) acting
on the RAS might affect cognition. Secondary analyses of
data between two large clinical trials to reduce the incidence
of stroke - the Systolic Hypertension in Europe (SYST-EUR)
trial (involving the ACE-I enalapril) and the Perindopril
Protection Against Recurrent Stroke Study (PROGRESS)
trial (involving the ACE-I perindopril) - found that the ACE-Is
reduced dementia and cognitive decline [8]. However,
perindopril inclusion in addition to indapamide in the
Hypertension in the Very Elderly Trial Cognitive Function
Assessment (HYVET-COG) trial made no difference to
dementia incidence [41]. Similarly, ACE-Is did not demon-
strate any protective benefit or other effects [42] in a recent
prospective study of new patients from a population in which
a prior retrospective analysis of the impact of anti-
hypertension medication use and incidence of dementia
found that ACE-Is demonstrated a trend towards incidence of
AD (adjusted hazard ratio = 1.13) despite anti-hypertensive
treatments in general being protective against AD [8].
Moreover, although the majority of existing data from
observational studies and secondary outcomes of trials are
derived from examination of ACE-Is on cognitive function,
there are also data suggesting that any perceived cognitive
benefits may be related more specifically to mechanisms
involving AngII and/or its derivatives (Figure 2). Losartan, an
ARB that can cross the BBB, was found to improve the
cognitive function and quality of life in people with
hypertension aged up to 73 years [43,44] but also has been
found to demonstrate positive benefits in both animal models
and human paradigms of cognition and anxiety that appear to
be independent of blood pressure changes and provide
interesting starting points that have yet to be followed
meaningfully in the context of AD or other dementias (see
[37] for an overview). Most studies to date suggest that anti-
hypertensive treatments acting on the RAS are of potential
use to reduce the incidence and/or rate of cognitive decline
in dementia; however, they need further validation since in
some of the previous studies the measures of cognition have
been limited when compared to the standards that would be
included in a trial designed for AD patients.
Can renin angiotensin system-inhibiting medications be
used to treat Alzheimer’s disease?
The potential benefits of ACE-Is in attenuating cognitive
decline are further supported by several small and larger
observational studies with more attention given to cognitive
measures and the diagnosis of AD. Overall, most findings
show that people taking ACE-Is had reduced incidence of AD
and that ACE-Is reduced rates of cognitive decline in people
with mild cognitive impairment [8,45,46]. However, the true
test of the therapeutic potential of any drug is a clinical trial.
With respect to specific studies of drugs acting on the RAS
in AD, two pilot trials of the not commonly used BBB-
crossing ACE-I ceranapril, which was shown to have delayed
but long lasting inhibitory actions on ACE activity in rat brains,
have been reported [47]. The first trial had a duration of
4 weeks and included 13 AD patients and 2 controls [48]
and the second trial was for 15 weeks and was a double
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patients [49]; both found no benefits to the patients involved,
although further analysis of the data from the second study
suggested that a study of longer duration and/or with higher
dosages was needed. Another 18-week cross-over trial of
perindopril on cognition in 16 very elderly hypertensive
people also found no treatment-related differences [50]. In
contrast, a randomised, prospective three-arm parallel group
trial conducted over 12 months on nearly 150 patients
reported that the so-called brain penetrating ACE-Is captopril
and perindopril reduced cognitive decline more effectively in
mild to moderate AD patients than the reputed non-brain
penetrating ACE-Is enalapril or imidapril, which performed the
same as the calcium channel blockers that served as the third
arm in the trial. After 1 year, the average rate of decline in the
perindopril/captopril-treated group was less than 1 Mini
Mental State Examination (MMSE) point compared with
changes of more than 4 points for the other two treatment
groups over the same time scale (reviewed in [8]).
It is clear that findings of the larger studies offer more
promising data and that there is now a need for further, more
rigorous studies to be conducted as well as studies that
examine ARBs in a similar context to offer meaningful
comparisons between ACE-I- and ARB-mediated effects.
Disparities between the earlier and later studies - apart from
their size differences, which may be significant - include the
duration of treatment and follow-up in patients but also
perhaps to a lesser extent that the threshold measurement by
which clinical hypertension is now diagnosed has been
revised [44]. Indeed, a further aspect needing consideration
in future trial designs is the peculiar relationship that exists
between hypertension and AD where increased hypertension
and serum cholesterol levels in midlife seem to be associated
with an increased incidence of AD in later life but also
decreased blood pressure and serum cholesterol levels in
later life appear to be associated with increased risk of AD at
a more advanced age [42]. This is further reinforced by the
finding from a study including a wide age range of elderly
subjects that the relationship between blood pressure and
cognition is not linear and the suggestion that there could be
an optimal level of blood pressure that supports optimal
cognitive function and that deviation from this increases the
likelihood or risk of cognitive decline [44].
Issues in the clinical application of drugs
affecting the renin angiotensin system
Alterations in various RAS components have been observed
consistently in various studies of AD. These consistent
findings can be seen across a range of studies, from
laboratory-based quantitative and qualitative investigations
involving genetic association studies and histological or
biochemical studies of human tissue samples through more
manipulable experimental systems involving cells and animals
to the most relevant population-based observational and
clinical trial related studies. The ACE-mediated Aβ
degradation model is interesting, particularly if baseline ACE
levels are genetically regulated. However, therein lies a
possible contradiction as to how genetic predisposition to
lower ACE levels or activity adversely affects ACE-mediated
Aβ degradation when ACE-Is, which also reduce ACE
activity, seem to be protective against both dementia and AD
incidence and cognitive decline (for a more in depth
discussion, see [8]). This may be partly explained by the
possibility that the association between ACE1 variation and
ACE levels is, in fact, relatively weak or that there are over-
riding changes to the normal regulation of ACE expression
and activity secondary to AD- or Aβ-related pathology. In
support of the latter hypothesis, we and others have shown
that there is elevated ACE activity in AD brain tissue that
appears to be independent of ACE1 variation and we have
also reported that cultured neuronal cells treated with
oligomeric Aβ peptides displayed increased ACE activity
after 24 hours [21]. Given the range of potentially deleterious
effects that can be mediated by AngII (including depression
of ACh release and inflammation), one can envisage possible
consequences of over-production or post-translational
modifications of ACE that could result in increased AngII
production. It is also possible to see how various
observational studies in mild cognitive impairment and AD
find ACE-Is and ARBs to be protective against AD incidence
and cognitive decline [8,45,46]. Other possible explanations
for the observed alterations in cognitive function could be
that the effects are driven by peripheral and not central
effects and/or the drugs in question may not penetrate the
BBB as well as originally thought, meaning that the potential
for interrupting Aβ degradation is less of an issue. It is
possible that ACE, AngII or any of the other factors involved
in the RAS, particularly the newly proposed internal regulatory
mechanisms in the RAS thought to work in opposition to
AngII [51] (Figure 2), may have yet-to-be-discovered func-
tions within the brain.
What is also clear is that further clinical trials of ACE-Is or
ARBs in AD are needed because, if these drugs are found to
be beneficial, they then provide the benefit of being
immediately available for, and amenable to, accelerated
testing and progression through what is normally a lengthy
drug discovery pipeline from initial compound discovery to
eventual implementation. However, the potential of these
compounds for use as symptomatic treatments will need to
be investigated in ways that are mindful of the possible
neuropathological consequences of using them if the results
from recent animal studies also apply to humans (although
this may not apply to ARBs) [33,34]. In addition to their use in
AD, there is now also a significant need to clarify whether
chronic use of ACE-Is, which offer a very effective means of
treating hypertension, may have any possible negative
consequences (for example, on a person’s Aβ degrading
potential) for particular subgroups of people. If such were
proven to be the case, then strong consideration will need to
be given as to whether their use in hypertension treatment
Alzheimer’s Research & Therapy    Vol 1 No 1 Kehoe
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preferable option as they may not interfere with ACE’s
degradation of Aβ.
Conclusion
Studies over the past two decades have added to our
knowledge of the pathways involved in the pathogenesis of
AD, including alterations to ACE and other angiotensin-
related components of the RAS. Whether these are primary
mediators or secondary consequences of the disease still
remains to be shown, however, and further studies are
certainly needed. There may be insufficient evidence at this
time with which to make a final judgement as to what benefit
or consequences ACE-Is or ARBs have on the development
or progression of AD, but there is sufficient evidence to justify
more measured consideration when prescribing ARBs or
ACE-Is for hypertension as well as active future study of how
pharmacological targeting of AngII in this pathway could offer
therapeutic value in mitigating against secondary pathogenic
Aβ-mediated changes in AD.
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